ORIGINAL INVESTIGATION. Effects of Prehypertension on Admissions and Deaths
|
|
- Blake Parks
- 5 years ago
- Views:
Transcription
1 ORIGINAL INVESTIGATION Effects of Prehypertension on Admissions and Deaths A Simulation Louise B. Russell, PhD; Elmira Valiyeva, PhD; Jeffrey L. Carson, MD Background: The Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure recently released new clinical practice guidelines that target systolic blood pressure and identify persons with prehypertension (systolic blood pressure, mm Hg), previously considered normal, as being at elevated risk and in need of intervention. Methods: We used a simulation model, fitted to longitudinal data from the first NHANES (National Health and Nutrition Examination Survey) Epidemiologic Followup Study, to estimate the effects of prehypertension and residual hypertension (systolic blood pressure, 140 mm Hg). The term residual hypertension recognizes that many people with hypertension have lowered their pressures through treatment, but not to less than 140 mm Hg. We applied the model to a representative sample of US adults aged 25 to 74 years from NHANES III. Results: Except for women aged 25 to 44 years, more than a third of each age group in NHANES III had prehypertension. Approximately two thirds of persons aged 45 to 64 years and 80% of persons aged 65 to 74 years had prehypertension or residual hypertension. Together, prehypertension and residual hypertension accounted for 4.7% of hospital admissions per adults aged 25 to 74 years, 9.7% of nursing home admissions, and 13.7% of deaths. Prehypertension alone accounted for 3.4% of hospitalizations, 6.5% of nursing home stays, and 9.1% of deaths. Numbers of events attributable to prehypertension are greatest for men aged 45 to 64 years and persons aged 65 to 74 years. Conclusions: Our results confirm the substantial public health consequences of prehypertension. If prehypertension were, hospitalizations, nursing home admissions, and premature deaths could decline substantially. Arch Intern Med. 2004;164: Author Affiliations: Institute for Health, Health Care Policy, and Aging Research and Department of Economics, Rutgers University (Drs Russell and Valiyeva), and Division of General Internal Medicine, University of Medicine and Dentistry of New Jersey, Robert Wood Johnson Medical School (Dr Carson), New Brunswick. Dr Valiyeva is now with the Department of Pharmacy Practice and Administration, Ernest Mario School of Pharmacy, Rutgers University, Piscataway, NJ. Financial Interest: None. ON MAY 14, 2003, THE NAtional Heart, Lung, and Blood Institute released new clinical practice guidelines for high blood pressure. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) was published a week later in The Journal of the American Medical Association. 1 The guidelines caught the attention of clinicians and the media with 2 changes in particular: they emphasized that systolic blood pressure (SBP), not diastolic BP, was the treatment target, and they defined a new category, prehypertension, which includes persons whose SBPs are 120 to 139 mm Hg; frank hypertension begins at 140 mm Hg. Systolic blood pressures in this range were previously considered normal. The new category includes 22% of American adults (approximately 45 million persons). 2 Then director of the National Heart, Lung, and Blood Institute, Claude Lenfant, MD, explained that [w]e also now know that damage to arteries beginsatfairlylowbloodpressurelevels thoseformerly considered normal and optimal. In fact, studies show that the risk of death from heart disease and stroke begins to rise at blood pressures as low as 115 over 75, and... doubles for each 20 over 10 millimeters of mercury increase. So theharmstartslongbeforepeoplegettreatment. 2 See also pages 2086 and 2113 Studies show that risk rises continuously as SBP increases and is independent of other risk factors. 1 The harm from SBPs in this range causes hospitalizations, nursing home admissions, and premature deaths. What share of admissions and deaths can be attributed to BPs in the prehypertension range? To contribute to a fuller picture of its public health consequences, we present estimates of hospital and nursing home admissions and deaths attributable to prehypertension in NHANES III (third National Health and Nutrition Examination Survey) adults aged 25 to 74 years. 2119
2 Cohort Dataset Contains Data on Baseline Risk Factors for NHANES III Sample Persons Aged y. Mortality Submodel For Each Person, Calculates the Probability of Dying During Each Year of the Projection Period. Derives Total Deaths for the Cohort. Hospital Admission Submodel For Each Person, Projects Hospital Admissions Each Year, Adjusted for Survival. Derives Total, Admission for the Cohort. METHODS Nursing Home Admissions Submodel For Persons Aged y, Projects Nursing Home Admissions Each Year, Adjusted for Survival. Derives Total Admissions for the Cohort. Figure. Structure of the simulation model. The projection equations in each submodel are based on the first National Health and Nutrition Examination Survey Epidemiologic Followup Study (see Methods section). Estimates are weighted before summing to reflect the person s share of the Third National Health and Nutrition Examination Survey population aged 25 to 74 years. The NHANES, large national surveys conducted by the National Center for Health Statistics, collect information about risk factors and health outcomes for representative samples of Americans. Our estimates are based on NHANES I and III. Fielded in 1971 through 1975, NHANES I is unique in having a longitudinal follow-up study (NHANES I Epidemiologic Followup Study [NHEFS]) that tracked hospitalizations, nursing home admissions, and deaths of participants for 2 decades, allowing baseline risk factors to be linked to subsequent outcomes. The NHEFS is the basis for our simulation model. The simulation model is applied to adults from NHANES III, fielded in 1988 through 1994, because the prevalence of risk factors in NHANES III, for example, more obesity and fewer smokers, better represents today s adults. We used the simulation model to estimate the effect of SBPs in the prehypertension range. The model relates hospitalizations, nursing home admissions, and deaths to baseline risk factors and has 4 components (Figure): the cohort data set, which contains baseline information for NHANES III adults aged 25 to 74 years; the mortality submodel, which projects all-cause mortality; and the hospitalization and nursing home submodels, which project all-cause admissions. The submodels use separate regressions, estimated with NHEFS data, for 6 age-sex groups: men aged 25 to 44, 45 to 64, and 65 to 74 years and women aged 25 to 44, 45 to 64, and 65 to 74 years; the NHEFS excluded older persons. The regressions relate hospitalizations, nursing home admissions, and mortality to all clinical risk factors that have been shown to be statistically significantly related to disease or death in multiplestudies: age, race, smoking, SBP, overweightandunderweight, laboratory test results (serum albumin, serum cholesterol, and hematocrit levels), exercise, alcohol consumption, diet (fiber, fish/ shellfish, andfruits/vegetables), and9groupsofchronicconditions. These risk factors are more fully described elsewhere. 3-5 Thus, the estimates of the effects of SBP are adjusted for other risk factors. Earlier published estimates 4-6 from the model used regressions fitted to the NHEFS through 1987 and were validated by in-sample and out-of-sample tests. For this study, the model was updated with data for 1988 through 1992, the final follow-up. Systolic BP is a statistically significant determinant of all 3 outcomes. 3,4,7 COHORT DATA SET The cohort data set includes all NHANES III respondents aged 25 to 74 years who were examined by a physician (N=12 841). Because 85% of respondents had complete information, 8% were missing data for only 1 risk factor, and only 24 individuals (0.19%) lacked data for more than 5 risk factors, we retained all sample persons and replaced missing values with the mean of that risk factor for the age-sex group. The NHANES I/NHEFS measured SBP only once. Thus, to match the projection equations, we used the first measurement of SBP in NHANES III. SIMULATION SUBMODELS The mortality and hospital submodels are described in detail elsewhere. 4,5 (The regressions are available on request from the authors.) The mortality submodel uses Weibull hazard functions to relate survival to the baseline risk factors. The hospital and nursing home submodels use negative binomial regressions to relate annual admissions to the same risk factors. The admissions submodels first estimate hospital (or nursing home) admissions for each individual and then adjust the estimates for the individual s probability of survival to the year in question (from the mortality submodel), as indicated in the Figure. Each sample person represents many people with similar characteristics in the US population, and this calculation is equivalent to estimating admissions for members of the group who are still alive in the specified year. SAMPLE WEIGHTS The NHANES III was a stratified cluster sample. We weighted the estimates for each participant to reflect his or her share of the US population of noninstitutionalized adults. Of several statistical weights available for the NHANES III, we used the examined sample final weight, because all individuals in our cohort underwent medical examination. ESTIMATES We calculated baseline estimates of hospitalizations, nursing home admissions, and deaths by entering observed baseline risk factors for the adults in the NHANES III cohort into the model regressions and running the model. Attributable-risk estimates were then calculated for 2 scenarios: (1) all persons with SBPs of 140 mm Hg or higher had their pressures reduced to 139 mm Hg (residual hypertension ), and (2) all persons with SBPs of 120 mm Hg or higher had their pressures reduced to 119 mm Hg (residual hypertension and prehypertension ). The term residual hypertension recognizes that many people with hypertension have lowered their pressures through treatment, although they have not achieved SBPs of less than 140 mm Hg. To estimate scenario 1, we identified all adults in the NHANES III cohort with recorded SBPs of 140 mm Hg or higher and set their pressures at 139 mm Hg. The model was run with these new values for SBP; all other risk factors remained at observed baseline levels for these individuals, and all risk factors, including BP, remained at baseline levels for individuals with observed SBPs of less than 140 mm Hg. The procedure was repeated for scenario 2 by identifying all adults with SBPs of 120 mm Hg or higher and setting their pressures at 119 mm Hg. The differences between the baseline and attributable-risk estimates represent hospital admissions, nursing home admissions, and deaths attributable to residual hypertension (baseline minus scenario 1) and to residual hypertension and prehypertension combined (baseline minus scenario 2). The differences between scenarios 1 and 2 represent events attributable to prehypertension alone. 2120
3 RESULTS Table 1 gives the percentages of NHANES III adults with SBPs of 140 mm Hg or higher (residual hypertension), 120 to 139 mm Hg (prehypertension), and 120 mm Hg or higher (residual hypertension and prehypertension), by age and sex. The group with residual hypertension, which includes people treated for hypertension but whose SBPs remained at 140 mm Hg or greater, accounts for a small percentage of persons aged 25 to 44 years, about a fifth of persons aged 45 to 64 years, and more than 40% of persons aged 65 to 74 years. The percentages with prehypertension are large more than a third of every agesex group except women aged 25 to 44 years. Together, persons with residual hypertension and prehypertension account for two thirds of persons aged 45 to 64 years and 80% of persons aged 65 to 74 years. Table 2 and Table 3 give hospital admissions, nursing home admissions, and deaths per persons in the first year of the projection period for baseline BP levels ( baseline ) and after the elimination of residual hypertension and prehypertension. Table 2 includes percentage reductions from baseline, and Table 3 includes absolute reductions in levels. ELIMINATING RESIDUAL HYPERTENSION If all NHANES III adults had SBPs of less than 140 mm Hg, hospital admissions per persons would be 1.3% lower; nursing home admissions, 3.2% lower; and deaths, 4.6% lower in the first year (Table 2). By the fifth year of the scenario, in which all adults have their SBPs reduced to less than 140 mm Hg (data not shown), the reductions would be slightly less: hospital admissions per persons would be 1.2% lower; nursing home admissions, 2.3% lower; and deaths, 4.0% lower. Women aged 65 to 74 years benefit most from elimination of residual hypertension. Their hospital admission rate declines 3.6% (Table 2), or by 55 admissions per persons (Table 3). Their percentage reductions in nursing home admissions and deaths are not the largest, but their higher event rates mean, again, that more events are avoided approximately 1 nursing home admission and 3 deaths per persons. ELIMINATING PREHYPERTENSION AND RESIDUAL HYPERTENSION Eliminating both prehypertension and residual hypertension would require further reductions in the SBPs of hypertensive persons and reductions in the SBPs of persons with prehypertension. If all NHANES III adults had SBPs of less than 120 mm Hg, hospital admissions per persons would be 4.7% lower; nursing home admissions, 9.7% lower; and deaths, 13.7% lower (Table 2). Again, reductions after 5 years are similar but slightly smaller (data not shown). The gains from eliminating prehypertension and residual hypertension, compared with eliminating residual hypertension alone, are substantial. Hospitalizations per persons decline 4.7%, compared with Table 1. NHANES III Adults With Residual Hypertension and Prehypertension, by Age and Sex* Sex and Age Residual Hypertension, % Prehypertension, % Total, % Men y y y Women y y y Abbreviation: NHANES III, Third National Health and Nutrition Examination Survey. *Values are weighted to represent noninstitutionalized US adults. Components may not add to total because of rounding. Residual hypertension is defined as systolic blood pressure of 140 mm Hg or higher, and prehypertension as systolic blood pressure of 120 to 139 mm Hg. 1.3% for residual hypertension alone; the difference of 3.4% is the additional gain from eliminating prehypertension (its attributable risk). For nursing home admissions and deaths, the gains from eliminating prehypertension are additional declines of 6.5% and 9.1%, respectively. Table 3 indicates that numbers of events avoided are greatest for women aged 65 to 74 years. Their hospital admissions decline by almost 150 per persons compared with baseline, an additional decline of more than 90 admissions per persons compared with eliminating residual hypertension alone. Eliminating prehypertension also avoids 2 more nursing home admissions and almost 5 more deaths per persons. Men aged 45 to 64 and 65 to 74 years show substantial reductions as well. For example, when prehypertension is, hospital admissions decline another 62 admissions per men aged 45 to 64 years and 41 admissions per men aged 65 to 74 years compared with eliminating only residual hypertension. COMMENT The authors of the JNC 7 1 state that the ultimate public health goal of antihypertensive therapy is the reduction of cardiovascular and renal morbidity and mortality. Our estimates show that if both residual hypertension and prehypertension could be, hospital admissions per persons would be 4.7% lower, nursing home admissions per persons would be 9.7% lower, and deaths per persons would be 13.7% lower. The effect of prehypertension is substantial: it accounts for 3.4, 6.5, and 9.1 percentage points, respectively, of these totals. Our estimates are for adults aged 25 to 74 years in NHANES III, a large, nationally representative survey conducted between 1988 and 1994 that provided data for the JNC 7 s deliberations. 1 In the editorial that accompanied the guidelines, Kottke et al 8 observe that hypertension awareness and control have not changed in the past decade (although a study 9 published more recently shows modest improvement in control). Thus, current conditions are similar to those in NHANES III. 2121
4 Table 2. Rates per Persons and Percentage Changes in Rates at Baseline and After Elimination of RHTN and PHTN, Year 1 Aged y Aged y Aged y Men Women Men Women Men Women Total Variable Rate Change, % Rate Change, % Rate Change, % Rate Change, % Rate Change, % Rate Change, % Rate Change, % Hospital admissions Baseline NA NA NA NA NA NA NA RHTN PHTN Nursing home admissions Baseline NE NE NE NE 6.1 NA 2.1 NA 27.2 NA 39.4 NA 12.4 NA RHTN NE NE NE NE PHTN NE NE NE NE Deaths Baseline 5.6 NA 2.4 NA 42.4 NA 7.0 NA 79.8 NA 46.3 NA 17.5 NA RHTN PHTN Abbreviations: NA, not applicable; NE, no estimate; PHTN, prehypertension; RHTN, residual hypertension. Table 3. Rates per Persons and Absolute Changes in Rates at Baseline and After Elimination of RHTN and PHTN, Year 1 Aged y Aged y Aged y Men Women Men Women Men Women Total Variable Rate Change, % Rate Change, % Rate Change, % Rate Change, % Rate Change, % Rate Change, % Rate Change, % Hospital admissions Baseline NA NA NA NA NA NA NA RHTN PHTN Nursing home admissions Baseline NE NE NE NE 6.1 NA 2.1 NA 27.2 NA 39.4 NA 12.4 NA RHTN NE NE NE NE PHTN NE NE NE NE Deaths Baseline 5.6 NA 2.4 NA 42.4 NA 7.0 NA 79.8 NA 46.3 NA 17.5 NA RHTN PHTN Abbreviations: NA, not applicable; NE, no estimate; PHTN, prehypertension; RHTN, residual hypertension. The new prehypertension category defined by the JNC 7 (SBP, mm Hg) means that many adults who were previously told that their pressures were normal will now be told that they are at heightened risk of cardiovascular disease. In each age-sex group considered herein, except women aged 25 to 44 years, more than one-third fall in the prehypertension range. Together with those classified as hypertensive (SBP, 140 mm Hg), almost two thirds of men and women aged 45 to 64 years and 80% of men and women aged 65 to 74 years are considered to be at risk. The JNC 7 emphasizes the risk to the elderly, noting not only that the prevalence of hypertension is highest in this group but also that rates of control are lowest. 1 Our estimates show that the potential gains from eliminating residual hypertension and prehypertension in the elderly are large. Although their percentage reductions are sometimes lower than those for younger groups, numbers of events avoided are the same or higher because of their high event rates. For example, the 9.6% reduction in hospitalizations per persons for women aged 65 to 74 years represents almost 150 fewer admissions per persons, more than 90 of them attributable to prehypertension. Numbers of events avoided are greatest for women and men in this age group and for men aged 45 to 64 years. The goal of treatment of hypertensive persons is to reduce their BP to 140/90 mm Hg or, if they have diabetes mellitus or kidney disease, to 130/80 mm Hg; most patients need to take 2 or more antihypertensive medications to achieve their goal. 1 The JNC 7 recommended life- 2122
5 style changes for those with prehypertension but did not specify a treatment target. Although 120 mm Hg is the lower boundary for the category, there is no recommendation that prehypertensive persons be treated to achieve SBPs of less than 120 mm Hg. Thus, even if the new guidelines are enthusiastically received, they are unlikely to yield gains of the magnitude we estimated. Our estimates serve, however, to confirm that prehypertension is an important health problem. Several limitations of our model should be noted. The diagnosis of hypertension or prehypertension in individuals is based on the average of 2 or more readings. 1 Our model is based on a single BP reading because only 1 was taken in the NHEFS, which is the basis for the projection equations. Our estimates of NHANES III adults with residual hypertension and prehypertension are thus higher than if the determinations were based on multiple readings. Nonetheless, our estimates for NHANES III adults of the outcomes attributable to residual hypertension and prehypertension are accurate, because our estimating equations, based on the NHEFS, self-correct for regression to the mean. The NHEFS followed up individuals for 2 decades and recorded their hospitalizations, nursing home admissions, and deaths. Individuals whose single baseline BPs were unusually high would have outcomes during follow-up in line with their true lower pressures. The equations linking outcomes to baseline BPs thus correct for regression to the mean, because persons whose BPs were overstated by a single reading contributed fewer events during follow-up than those with genuinely elevated BPs. When the equations were applied to the single BP readings for NHANES III adults, they again estimated outcomes corrected for regression to the mean. We limited our projections to the first and fifth years of the projection period. Thus, the projections are primarily based on the first 5 years of the NHEFS and should model the natural history of hypertension/prehypertension well. In the 1970s, the efficacy of drug treatment for hypertension was being documented. Not until 1980 did the JNC publish its first recommendations advocating treatment for people with moderate or severe hypertension, and not until 1984 did it extend its recommendations to people with SBPs as low as 140 mm Hg. Nonetheless, our estimates understate the gains from controlling hypertension, because by , when NHANES III was conducted, hypertension was often treated aggressively, so SBPs observed in NHANES III were lower than they would have been naturally. Thus, although the projection equations reflect the natural history of hypertension, the population to which they are applied, NHANES III adults, included many individuals whose SBPs had already been lowered through treatment. For that reason, we referred to these estimates as showing the effects of residual hypertension. This limitation does not apply to individuals with prehypertension, who, until the JNC 7, were considered normal and were not treated. Thus, our estimates for prehypertension reflect the full effects of this condition its attributable risk. However, to fully validate the concept of prehypertension, it will be necessary to demonstrate through clinical trials that treatment with diet or medication reduces mortality, morbidity, or hospitalizations. Very large trials are needed to establish efficacy of treatment for prehypertension and to determine the extent to which treatment can reduce risk. Finally, national trends during the NHEFS suggested that our hospitalization estimates might be high. Hospitalization rates measured by the National Hospital Discharge Survey (NHDS) increased between 1970 and the early 1980s, then fell until the early 1990s; they continued to decline through 2000 for persons aged 45 to 64 years, but they rose again for persons 65 years or older. 10 The NHDS rates should exceed those for NHANES III (and NHANES I) adults, because NHANES participants were drawn from the noninstitutionalized population. In addition, because they were able to travel to an examination site, they may have been even healthier than the general noninstitutionalized population. To check that our estimates are reasonable, we compared year 1 hospitalization rates with NHDS rates for the same age-sex groups. As they should be, our estimates were uniformly lower (60%-80% of NHDS rates). By introducing the category of prehypertension, the JNC 7 1 has focused attention on lifestyle and its effects. The report 1 notes that lifestyle modifications... [are]... critical for the prevention of high BP and an indispensable part of the management of those with hypertension. The accompanying editorial 8 states The JNC 7 report is about more than hypertension. For many, high blood pressure is just one manifestation of what may be termed the lifestyle syndrome, which is a cluster of conditions and diseases that result from consuming too many calories; ingesting too much saturated fat, sodium, and alcohol; not expending enough calories; and using tobacco or being exposed to tobacco smoke. The reductions in hospitalizations, nursing home admissions, and deaths that might result from eliminating prehypertension and residual hypertension are thus only part of the potential impact of lifestyle change. The total effect could be much larger. Our estimates show that if means can be found to prevent prehypertension in addition to hypertension, the reductions in hospital and nursing home admissions and deaths would be substantial. Residual hypertension and prehypertension together accounted for 4.7% of hospital admissions per US adults aged 25 to 74 years, 9.7% of nursing home admissions, and 13.7% of deaths. In each case, prehypertension by itself was responsible for approximately two thirds of the excess admissions and deaths. Accepted for Publication: February 27, Correspondence: Louise B. Russell, PhD, Institute for Health, Health Care Policy, and Aging Research, Rutgers University, 30 College Ave, New Brunswick, NJ (lrussell@ihhcpar.rutgers.edu). Funding/Support: Development of the simulation model used for this study was supported in part by grants HS07002 and HS11477 from the Agency for Healthcare Research and Quality, Rockville, Md. 2123
6 REFERENCES 1. Chobanian AV, Bakris GL, Black HR, et al; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289: NHLBI issues new high blood pressure clinical practice guidelines. News NIH. Available at: Accessed May 15, Miller JE, Russell LB, Davis DM, Milan E, Carson JL, Taylor WC. Biomedical risk factors for hospital admission in older adults. Med Care. 1998;36: Russell LB, Carson JL, Taylor WC, Milan E, Dey A, Jagannathan R. Modeling allcause mortality: estimates of the impact of smoking cessation based on the NHEFS. Am J Public Health. 1998;88: Russell LB, Teutsch SM, Kumar R, Dey A, Milan E. Preventable smoking and exercise-related hospital admissions: a model based on the NHEFS. AmJPrevMed. 2001;20: Russell LB, Valiyeva E. Projecting the Consequences of Better Health for Older Adults: Final Report. Submitted to Agency for Healthcare Research and Quality; January Valiyeva E, Russell LB, Miller JE. Health history, health behaviors, and risk of nursing home admission over two decades: the NHANES I Epidemiologic Followup Study. Working paper. 8. Kottke TE, Stroebel RJ, Hoffman RS. JNC 7: it s more than high blood pressure [editorial]. JAMA. 2003;289: Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, JAMA. 2003;290: Hall MJ, Owings MF. National Hospital Discharge Survey. Adv Data. 2002;329: Correction Error in Acknowledgments. In the article by Hardin and Yusufaly titled Difficult End-of-life Treatment Decisions: Do Other Factors Trump Advance Directives? published in the July 26 issue of the ARCHIVES (2004;164: ), information about a previous presentation of the study was omitted. A paragraph in the acknowledgments should have read: This study was presented in poster form at the annual meeting of the Society of Internal Medicine; May 5-6, 2000; Boston, Mass. 2124
Hospitalizations, Nursing Home Admissions, and Deaths Attributable to Diabetes
Epidemiology/Health Services/Psychosocial Research O R I G I N A L A R T I C L E Hospitalizations, Nursing Home Admissions, and Deaths Attributable to Diabetes LOUISE B. RUSSELL, PHD 1,2 ELMIRA VALIYEVA,
More informationHypertension. Risk of cardiovascular disease beginning at 115/75 mmhg doubles with every 20/10mm Hg increase. (Grade B)
Practice Guidelines and Principles: Guidelines and principles are intended to be flexible. They serve as reference points or recommendations, not rigid criteria. Guidelines and principles should be followed
More informationInt. J. Pharm. Sci. Rev. Res., 36(1), January February 2016; Article No. 06, Pages: JNC 8 versus JNC 7 Understanding the Evidences
Research Article JNC 8 versus JNC 7 Understanding the Evidences Anns Clara Joseph, Karthik MS, Sivasakthi R, Venkatanarayanan R, Sam Johnson Udaya Chander J* RVS College of Pharmaceutical Sciences, Coimbatore,
More informationA Needs Assessment of Hypertension in Georgia
A Needs Assessment of Hypertension in Georgia Faye Lopez Mercer University School of Medicine Marylen Rimando Mercer University School of Medicine Harshali Khapekar Mercer University School of Medicine
More informationNIH Public Access Author Manuscript JAMA Intern Med. Author manuscript; available in PMC 2015 August 01.
NIH Public Access Author Manuscript Published in final edited form as: JAMA Intern Med. 2014 August ; 174(8): 1397 1400. doi:10.1001/jamainternmed.2014.2492. Prevalence and Characteristics of Systolic
More informationUsing Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly
Using Cardiovascular Risk to Guide Antihypertensive Treatment Implications For The Pre-elderly and Elderly Paul Muntner, PhD MHS Professor and Vice Chair Department of Epidemiology University of Alabama
More informationARIC Manuscript Proposal # PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority:
ARIC Manuscript Proposal # 1475 PC Reviewed: 2/10/09 Status: A Priority: 2 SC Reviewed: Status: Priority: 1.a. Full Title: Hypertension, left ventricular hypertrophy, and risk of incident hospitalized
More informationBlood Pressure Assessment Practices of Dental Hygienists
Blood Pressure Assessment Practices of Dental Hygienists Abstract An estimated 50 million Americans have high blood pressure (HBP), with 30% of them unaware of their condition. Both the American Dental
More informationChronic kidney disease (CKD) has received
Participant Follow-up in the Kidney Early Evaluation Program (KEEP) After Initial Detection Allan J. Collins, MD, FACP, 1,2 Suying Li, PhD, 1 Shu-Cheng Chen, MS, 1 and Joseph A. Vassalotti, MD 3,4 Background:
More informationMANAGEMENT OF HYPERTENSION: TREATMENT THRESHOLDS AND MEDICATION SELECTION
Management of Hypertension: Treatment Thresholds and Medication Selection Robert B. Baron, MD MS Professor and Associate Dean Declaration of full disclosure: No conflict of interest Presentation Goals
More informationHypertension Guidelines 2017
Hypertension Guidelines 2017 (American College of Cardiology and the American Heart Association) In 1977, the 1st comprehensive guideline for detection, evaluation, and management of high BP was published,
More informationHypertension awareness, treatment, and control
O r i g i n a l P a p e r Prevalence of Self-Reported High Blood Pressure Awareness, Advice Received From Health Professionals, and Actions Taken to Reduce High Blood Pressure Among US Adults Healthstyles
More informationDISCLOSURE PHARMACIST OBJECTIVES 9/30/2014 JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES. I have nothing to disclose.
JNC 8: A REVIEW OF THE LONG-AWAITED/MUCH-ANTICIPATED HYPERTENSION GUIDELINES Tiffany Dickey, PharmD Assistant Professor, UAMS COP Clinical Pharmacy Specialist, Mercy Hospital Northwest AR DISCLOSURE I
More informationUsing the New Hypertension Guidelines
Using the New Hypertension Guidelines Kamal Henderson, MD Department of Cardiology, Preventive Medicine, University of North Carolina School of Medicine Kotchen TA. Historical trends and milestones in
More informationHYPERTENSION: ARE WE GOING TOO LOW?
HYPERTENSION: ARE WE GOING TOO LOW? George L. Bakris, M.D.,F.A.S.N.,F.A.S.H., F.A.H.A. Professor of Medicine Director, ASH Comprehensive Hypertension Center University of Chicago Medicine Chicago, IL USA
More informationNBER WORKING PAPER SERIES THE IMPACT OF ANTIHYPERTENSIVE DRUGS ON THE NUMBER AND RISK OF DEATH, STROKE AND MYOCARDIAL INFARCTION IN THE UNITED STATES
NBER WORKING PAPER SERIES THE IMPACT OF ANTIHYPERTENSIVE DRUGS ON THE NUMBER AND RISK OF DEATH, STROKE AND MYOCARDIAL INFARCTION IN THE UNITED STATES Genia Long David Cutler Ernst R. Berndt Jimmy Royer
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
PREVENTING CARDIOVASCULAR DISEASE IN WOMEN: Current Guidelines for Hypertension, Lipids and Aspirin Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationFor instance, it can harden the arteries, decreasing the flow of blood and oxygen to the heart. This reduced flow can cause
High Blood Pressure Blood pressure is the force of blood against your artery walls as it circulates through your body. Blood pressure normally rises and falls throughout the day, but it can cause health
More informationNew Hypertension Guideline Recommendations for Adults July 7, :45-9:30am
Advances in Cardiovascular Disease 30 th Annual Convention and Reunion UERM-CMAA, Inc. Annual Convention and Scientific Meeting July 5-8, 2018 New Hypertension Guideline Recommendations for Adults July
More informationHYPERTENSION: UPDATE 2018
HYPERTENSION: UPDATE 2018 From the Cardiologist point of view Richard C Padgett, MD I have no disclosures HYPERTENSION ALWAYS THE ELEPHANT IN THE EXAM ROOM BUT SOMETIMES IT CHARGES HTN IN US ~78 million
More informationCardiovascular Disease Risk Factors and Blood Pressure Control in Ambulatory Care Visits to Physician Offices in the U.S.
Cardiovascular Disease Risk Factors and Blood Pressure Control in Ambulatory Care Visits to Physician Offices in the U.S. Item Type Thesis Authors Couch, Christopher Rights Copyright is held by the author.
More informationHypertension in 2015: SPRINT-ing ahead of JNC-8. MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic
Hypertension in 2015: SPRINT-ing ahead of JNC-8 MAJ Charles Magee, MD MPH FACP Director, WRNMMC Hypertension Clinic Conflits of interest? None Disclaimer The opinions contained herein are not to be considered
More informationPrevalence, awareness of hypertension in rural areas of Kurnool
Original article: Prevalence, awareness of hypertension in rural areas of Kurnool Dr. Sudhakar Babu*, Dr.Aruna MS** *Associate Professor, Dept of Community Medicine, Vishwa Bharathi Medical College Kurnool,
More informationClinical Recommendations: Patients with Periodontitis
The American Journal of Cardiology and Journal of Periodontology Editors' Consensus: Periodontitis and Atherosclerotic Cardiovascular Disease. Friedewald VE, Kornman KS, Beck JD, et al. J Periodontol 2009;
More informationORIGINAL INVESTIGATION. C-Reactive Protein Concentration and Incident Hypertension in Young Adults
ORIGINAL INVESTIGATION C-Reactive Protein Concentration and Incident Hypertension in Young Adults The CARDIA Study Susan G. Lakoski, MD, MS; David M. Herrington, MD, MHS; David M. Siscovick, MD, MPH; Stephen
More informationAnalytical Methods: the Kidney Early Evaluation Program (KEEP) The Kidney Early Evaluation program (KEEP) is a free, community based health
Analytical Methods: the Kidney Early Evaluation Program (KEEP) 2000 2006 Database Design and Study Participants The Kidney Early Evaluation program (KEEP) is a free, community based health screening program
More informationCardiovascular Health Practice Guideline Outpatient Management of Coronary Artery Disease 2003
Authorized By: Medical Management Guideline Committee Approval Date: 12/13/01 Revision Date: 12/11/03 Beta-Blockers Nitrates Calcium Channel Blockers MEDICATIONS Indicated in post-mi, unstable angina,
More informationBROUGHT TO YOU BY. Blood Pressure
BROUGHT TO YOU BY Blood Pressure High blood pressure usually has no warning signs or symptoms, so many people don't realize they have it. According to the Center of Disease Control, CDC, about 75 million
More informationDEPARTMENT OF GENERAL MEDICINE WELCOMES
DEPARTMENT OF GENERAL MEDICINE WELCOMES 1 Dr.Mohamed Omar Shariff, 2 nd Year Post Graduate, Department of General Medicine. DR.B.R.Ambedkar Medical College & Hospital. 2 INTRODUCTION Leading cause of global
More informationΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ. Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH
ΑΡΥΙΚΗ ΠΡΟΔΓΓΙΗ ΤΠΔΡΣΑΙΚΟΤ ΑΘΔΝΟΤ Μ.Β.Παπαβαζιλείοσ Καρδιολόγος FESC - Γιεσθύνηρια ιζμανόγλειον ΓΝΑ Clinical Hypertension Specialist ESH Hypertension Co-Morbidities HTN Commonly Clusters with Other Risk
More informationHypertension Management Controversies in the Elderly Patient
Hypertension Management Controversies in the Elderly Patient Juan Bowen, MD Geriatric Update for the Primary Care Provider November 17, 2016 2016 MFMER slide-1 Disclosure No financial relationships No
More informationUpdate in Hypertension
Update in Hypertension Eliseo J. PérezP rez-stable MD Professor of Medicine DGIM, Department of Medicine UCSF 20 May 2008 Declaration of full disclosure: No conflict of interest (I have never been funded
More informationOptimal blood pressure targets in chronic kidney disease
Optimal blood pressure targets in chronic kidney disease Pr. Michel Burnier Service of Nephrology and Hypertension University Hospital Lausanne Switzerland Evidence-Based Guideline for the Management
More information2/11/2019 CLINICAL IMPLEMENTATION OF THE UPDATED BP GUIDELINES DUALITY OF INTEREST
CLINICAL IMPLEMENTATION OF THE UPDATED BP GUIDELINES George L. Bakris, M.D.,F.A.S.N., F.A.H.A. Professor of Medicine Director, Am Heart Assoc. Comprehensive Hypertension Center University of Chicago Medicine
More information2. Measurement Specifications 3. Patient Messaging 4. Provider Messaging Other Recent Guidelines
Measure Up/Pressure Down Response to the Release of 2014 Evidence-Based Guideline for the Management of High Blood Pressure in Adults: Report from the Panel Members Appointed to the Eighth Joint National
More informationNew Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets
New Recommendations for the Treatment of Hypertension: From Population Salt Reduction to Personalized Treatment Targets Sidney C. Smith, Jr. MD, FACC, FAHA Professor of Medicine/Cardiology University of
More informationCardiovascular Disease Prevention: Current Knowledge, Future Directions
Cardiovascular Disease Prevention: Current Knowledge, Future Directions Daniel Levy, MD Director, Framingham Heart Study Professor of Medicine, Boston University School of Medicine Editor-in-Chief, Journal
More informationManaging HTN in the Elderly: How Low to Go
Managing HTN in the Elderly: How Low to Go Laxmi S. Mehta, MD, FACC The Ohio State University Medical Center Assistant Professor of Clinical Internal Medicine Clinical Director of the Women s Cardiovascular
More informationPreventing heart disease by controlling hypertension: Impact of hypertensive subtype, stage, age, and sex
Prevention and Rehabilitation Preventing heart disease by controlling hypertension: Impact of hypertensive subtype, stage, age, and sex Nathan D. Wong, PhD, a Gaurav Thakral, BS, a Stanley S. Franklin,
More informationHypertension in the very old. Objectives: Clinical Perspective
Harvard Medical School Hypertension in the very old Ihab Hajjar, MD, MS, AGSF Associate Director, CV Research Lab Assistant Professor of Medicine, Harvard Medical School Objectives: Describe the clinical
More information4/7/ The stats on heart disease. + Deaths & Age-Adjusted Death Rates for
+ Update on Lipid Management Stacey Gardiner, MD Assistant Professor Division of Cardiovascular Medicine Medical College of Wisconsin + The stats on heart disease Over the past 10 years for which statistics
More informationT. Suithichaiyakul Cardiomed Chula
T. Suithichaiyakul Cardiomed Chula The cardiovascular (CV) continuum: role of risk factors Endothelial Dysfunction Atherosclerosis and left ventricular hypertrophy Myocardial infarction & stroke Endothelial
More information2017 USRDS ANNUAL DATA REPORT KIDNEY DISEASE IN THE UNITED STATES S611
Healthy People 2020 In this chapter, we examine data for 11 Healthy People 2020 (HP2020) objectives 10 for CKD and one for diabetes spanning 20 total indicators for which the USRDS serves as the official
More informationS150 KEEP Analytical Methods. American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153
S150 KEEP 2009 Analytical Methods American Journal of Kidney Diseases, Vol 55, No 3, Suppl 2, 2010:pp S150-S153 S151 The Kidney Early Evaluation program (KEEP) is a free, communitybased health screening
More informationDeclaration of Conflict of Interest. No potential conflict of interest to disclose with regard to the topics of this presentations.
Declaration of Conflict of Interest No potential conflict of interest to disclose with regard to the topics of this presentations. Clinical implications of smoking relapse after acute ischemic stroke Furio
More informationTennessee Department of Health in collaboration with Tennessee State University and University of Tennessee Health Science Center
Tennessee Department of Health in collaboration with Tennessee State University and University of Tennessee Health Science Center 2006 Tennessee Department of Health 2006 ACKNOWLEDGEMENTS CONTRIBUTING
More informationmajor public health burden
HYPERTENSION INTRODUCTION Hypertension is one of the major public health burden in the recent times. Hypertension remains a challenging medical condition among the noncommunicable diseases of ever growing
More informationData Fact Sheet. Congestive Heart Failure in the United States: A New Epidemic
National Heart, Lung, and Blood Institute Data Fact Sheet Congestive Heart Failure National Heart, Lung, and Blood Institute National Institutes of Health Data Fact Sheet Congestive Heart Failure in the
More informationHypertension JNC 8 (2014)
Hypertension JNC 8 (2014) Renewed: February 2018 Updated: February 2015 Comparison of Seventh Joint National Committee (JNC 7) vs. Eighth Joint National Committee (JNC 8) Hypertension Guidelines Methodology
More informationConflict of Interest Disclosure. Learning Objectives. Learning Objectives. Guidelines. Update on Lifestyle Guidelines
Conflict of Interest Disclosure Updates for the Ambulatory Care Pharmacist: Dyslipidemia and CV Risk Assessment No conflicts of interest to disclose 2014 Updates to the Updates in Ambulatory Care Pharmacy
More informationPrevalence of Hypertension in Semi-Urban area of Nepal
ORIGINAL ARTICLE Prevalence of Hypertension in Semi-Urban area of Nepal Koju R*, Manandhar K*, Gurung R*, Pant P*, Bedi TRS* *Department of Internal Medicine, Dhulikhel Hospital KUH ABSTRACT Hypertension
More information4/4/17 HYPERTENSION TARGETS: WHAT DO WE DO NOW? SET THE STAGE BP IN CLINICAL TRIALS?
HYPERTENSION TARGETS: WHAT DO WE DO NOW? MICHAEL LEFEVRE, MD, MSPH PROFESSOR AND VICE CHAIR DEPARTMENT OF FAMILY AND COMMUNITY MEDICINE UNIVERSITY OF MISSOURI 4/4/17 DISCLOSURE: MEMBER OF THE JNC 8 PANEL
More informationStatistical Fact Sheet Populations
Statistical Fact Sheet Populations At-a-Glance Summary Tables Men and Cardiovascular Diseases Mexican- American Males Diseases and Risk Factors Total Population Total Males White Males Black Males Total
More informationLow-Carbohydrate Diets and All-Cause and Cause-Specific Mortality: A Population-based Cohort Study and Pooling Prospective Studies
Low-Carbohydrate Diets and All-Cause and Cause-Specific Mortality: A Population-based Cohort Study and Pooling Prospective Studies Mohsen Mazidi 1, Niki Katsiki 2, Dimitri P. Mikhailidis 3, Maciej Banach
More informationCONTRIBUTING FACTORS FOR STROKE:
CONTRIBUTING FACTORS FOR STROKE: HYPERTENSION AND HYPERCHOLESTEROLEMIA Melissa R. Stephens, MD, FAAFP Associate Professor of Clinical Sciences William Carey University College of Osteopathic Medicine LEARNING
More informationNorthwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient?
Northwestern University Feinberg School of Medicine Calculating the CVD Risk Score: Which Tool for Which Patient? Donald M. Lloyd-Jones, MD, ScM, FACC, FAHA Senior Associate Dean Chair, Department of Preventive
More informationClinical Guidelines. Annals of Internal Medicine. Annals of Internal Medicine
Annals of Internal Medicine Clinical Guidelines Screening for High Blood Pressure: U.S. Preventive Services Task Force Reaffirmation Recommendation Statement U.S. Preventive Services Task Force* Description:
More informationISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW
ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP OVERVIEW 2014 PQRS OPTIONS F MEASURES GROUPS: 2014 PQRS MEASURES IN ISCHEMIC VASCULAR DISEASE (IVD) MEASURES GROUP: #204. Ischemic Vascular Disease (IVD):
More informationNo relevant financial relationships
MANAGEMENT OF LIPID DISORDERS Balancing Benefits and harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial relationships baron@medicine.ucsf.edu
More informationHealth Benefits of Lowering Sodium Intake in the US
Health Benefits of Lowering Sodium Intake in the US Lawrence J Appel, MD, MPH Professor of Medicine, Epidemiology and International Health (Human Nutrition) Director, Welch Center for Prevention, Epidemiology
More informationA n aly tical m e t h o d s
a A n aly tical m e t h o d s If I didn t go to the screening at Farmers Market I would not have known about my kidney problems. I am grateful to the whole staff. They were very professional. Thank you.
More informationLessons learned from AASK (African-American Study of Kidney Disease and Hypertension)
Lessons learned from AASK (African-American Study of Kidney Disease and Hypertension) Janice P. Lea, MD, MSc, FASN Professor of Medicine Chief Medical Director of Emory Dialysis ASH Clinical Specialist
More informationWhy Do We Treat Obesity? Epidemiology
Why Do We Treat Obesity? Epidemiology Epidemiology of Obesity U.S. Epidemic 2 More than Two Thirds of US Adults Are Overweight or Obese 87.5 NHANES Data US Adults Age 2 Years (Crude Estimate) Population
More informationJared Moore, MD, FACP
Hypertension 101 Jared Moore, MD, FACP Assistant Program Director, Internal Medicine Residency Clinical Assistant Professor of Internal Medicine Division of General Medicine The Ohio State University Wexner
More informationClinical Therapeutics/Volume 33, Number 1, 2011
Clinical Therapeutics/Volume 33, Number 1, 2011 Concurrent Control of Blood Glucose, Body Mass, and Blood Pressure in Patients With Type 2 Diabetes: An Analysis of Data From Electronic Medical Records
More informationVascular and Degenerative Causes of Cognitive Impairment: How are they linked?
Vascular and Degenerative Causes of Cognitive Impairment: How are they linked? MCI Symposium, Public Education Forum Presented by: Rebecca Gottesman, MD PhD January 20, 2019 1 Disclosures I am an Associate
More informationTrends in Prevalence, Awareness, Management, and Control of Hypertension Among United States Adults, 1999 to 2010
Journal of the American College of Cardiology Vol. 60, No. 7, 2012 2012 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.04.026
More informationPage down (pdf converstion error)
1 of 6 2/10/2005 7:57 PM Weekly August6, 1999 / 48(30);649-656 2 of 6 2/10/2005 7:57 PM Achievements in Public Health, 1900-1999: Decline in Deaths from Heart Disease and Stroke -- United States, 1900-1999
More informationDirector of the Israeli Institute for Quality in Medicine Israeli Medical Association July 1st, 2016
The differential effect of Atherosclerosis on end organ damage in adult and elderly patients with CVRF: New Algorithm for Hypertension Diagnosis and Treatment R. Zimlichman, FAHA, FASH, FESC, FESH Chief
More informationPrescription Pattern of Anti-Hypertensive Drugs in Adherence to JNC- 7 Guidelines
American Journal of Pharmacology and Toxicology Original Research Paper Prescription Pattern of Anti-Hypertensive Drugs in Adherence to JNC- 7 Guidelines 1 Krishna Murti, 1 M. Arif Khan, 1 Akalanka Dey,
More informationWhat is hypertension?
HYPERTENSION What is hypertension? Abnormally elevated arterial blood pressure that is usually indicated by an adult systolic blood pressure of 140 mm Hg or greater or a diastolic blood pressure of 90
More information2017 High Blood Pressure Clinical Practice Guideline
2017 High Blood Pressure Clinical Practice Guideline Applying the Latest Hypertension Guideline to Your Practice Carmine D Amico, D.O., F.A.C.C. 2017 ACC / AHA / AAPA / ABC / ACPM / AGS / APhA / ASH /
More informationDiversity and HTN: Approaches to optimal BP control in AfricanAmericans
Diversity and HTN: Approaches to optimal BP control in AfricanAmericans Quinn Capers, IV, MD, FACC, FSCAI Assistant Professor of Medicine Associate Dean for Admissions Do Racial Differences Really Exist
More informationThe prevalence of hypertension in a representative
CLINICAL STRATEGIES FOR OPTIMAL HYPERTENSION MANAGEMENT Roger S. Blumenthal, MD * ABSTRACT In the United States, approximately 25% of the adult population older than 40 years has hypertension. Americans
More informationWhat is Your Hypertension IQ?
What is Your Hypertension IQ? By: James L. Holly, MD Question: If you are 55 years of age and if you do not have high blood pressure -- hypertension -- what is your risk of developing blood pressure in
More informationSupplementary Online Content
Supplementary Online Content Yang Q, Zhang Z, Gregg EW, Flanders WD, Merritt R, Hu FB. Added sugar intake and cardiovascular diseases mortality among US adults. JAMA Intern Med. Published online February
More informationRESISTENT HYPERTENSION. Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University
RESISTENT HYPERTENSION Dr. Helmy Bakr Professor and Head of Cardiology Dept. Mansoura University Resistant Hypertension Blood pressure remaining above goal in spite of concurrent use of 3 antihypertensive
More informationAndrew Cohen, MD and Neil S. Skolnik, MD INTRODUCTION
2 Hyperlipidemia Andrew Cohen, MD and Neil S. Skolnik, MD CONTENTS INTRODUCTION RISK CATEGORIES AND TARGET LDL-CHOLESTEROL TREATMENT OF LDL-CHOLESTEROL SPECIAL CONSIDERATIONS OLDER AND YOUNGER ADULTS ADDITIONAL
More informationEffective Date: TBD Version: 1.0 (Revised: 6/11/2014)
Protocol Title: Hypertension Effective Date: TBD Version: 1.0 (Revised: 6/11/2014) Approval By: TBD Planned Review Date: TBD 1 Purpose & Objective This protocol provides evidence-based care recommendations
More informationUSRDS UNITED STATES RENAL DATA SYSTEM
USRDS UNITED STATES RENAL DATA SYSTEM Chapter 10: Dialysis Providers In 2013, collectively the three large dialysis organizations treated 71% of patients in 67% of all dialysis units. In the Small Dialysis
More informationBiostats Final Project Fall 2002 Dr. Chang Claire Pothier, Michael O'Connor, Carrie Longano, Jodi Zimmerman - CSU
Biostats Final Project Fall 2002 Dr. Chang Claire Pothier, Michael O'Connor, Carrie Longano, Jodi Zimmerman - CSU Prevalence and Probability of Diabetes in Patients Referred for Stress Testing in Northeast
More informationReport Operation Heart to Heart
Report Operation Heart to Heart Elkhorn Logan Valley Public Health Department (Burt, Cuming, Madison, and Stanton Counties) Gina Uhing, Health Director Ionia Research Newcastle, Nebraska Joseph Nitzke
More informationDiscontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database
open access Discontinuation and restarting in patients on statin treatment: prospective open cohort study using a primary care database Yana Vinogradova, 1 Carol Coupland, 1 Peter Brindle, 2,3 Julia Hippisley-Cox
More informationOsama Sanad (MD) Prof. of Cardiology Benha University 2016
Osama Sanad (MD) Prof. of Cardiology Benha University 2016 Back in time. 1912 Back in time. 1912 No body knows that hypertension is a lethal disease Hypertension in 1940s Among anti-hypertensives mentioned
More information7/6/2012. University Pharmacy 5254 Anthony Wayne Drive Detroit, MI (313)
University Pharmacy 5254 Anthony Wayne Drive Detroit, MI 48202 (313) 831-2008 Be able to identify the signs of a heart attack or stoke Identify what puts you at a higher risk for cardiovascular disease,
More informationDisclosure. No relevant financial relationships. Placebo-Controlled Statin Trials
MANAGEMENT OF HYPERLIPIDEMIA AND CARDIOVASCULAR RISK IN WOMEN: Balancing Benefits and Harms Disclosure Robert B. Baron, MD MS Professor and Associate Dean UCSF School of Medicine No relevant financial
More informationHYPERTENSION IS A MAJOR RISK
ORIGINAL CONTRIBUTION Trends in Prevalence, Awareness, Treatment, and Control of Hypertension in the United States, 1988-2000 Ihab Hajjar, MD, MS Theodore A. Kotchen, MD Context Prior analyses of National
More informationHypertension Guidelines: Lessons for Primary Care. Paul A James MD Professor and Chair Department of Family Medicine University of Washington
Hypertension Guidelines: Lessons for Primary Care Paul A James MD Professor and Chair Department of Family Medicine University of Washington Disclaimer and Financial Disclosure I have no financial interests
More informationThe NALC Health Benefit Plan HBR Report
The NALC Health Benefit Plan HBR Report Vol. 18-3 Fredric V. Rolando, President Brian Hellman, Director May 2018 20547 Waverly Court Ashburn, VA 20149-703.729.4677. Board of Trustees Lawrence D. Brown,
More informationJNC Evidence-Based Guidelines for the Management of High Blood Pressure in Adults
JNC 8 2014 Evidence-Based Guidelines for the Management of High Blood Pressure in Adults Table of Contents Why Do We Treat Hypertension? Blood Pressure Treatment Goals Initial Therapy Strength of Recommendation
More information5. Cardiovascular Disease & Stroke
5. Cardiovascular Disease & Stroke 64: Self-Reported Heart Disease 66: Heart Disease Management 68: Heart Disease Mortality 70: Heart Disease Mortality Across Life Span 72: Stroke Mortality 185: Map 3:
More informationHypertension and the SPRINT Trial: Is Lower Better
Hypertension and the SPRINT Trial: Is Lower Better 8th Annual Orange County Symposium on Cardiovascular Disease Prevention Saturday, October 8, 2016 Keith C. Norris, MD, PhD, FASN Professor of Medicine,
More informationLong-Term Care Updates
Long-Term Care Updates August 2015 By Darren Hein, PharmD Hypertension is a clinical condition in which the force of blood pushing on the arteries is higher than normal. This increases the risk for heart
More informationHypertension and Cholesterol in the Elderly
Hypertension and Cholesterol in the Elderly Angela Sanford, MD Assistant Professor of Geriatrics Saint Louis University School of Medicine I have no relevant financial disclosures Cushman WC. The burden
More informationClinical Practice Guideline
Clinical Practice Guideline Secondary Prevention for Patients with Coronary and Other Vascular Disease Since the 2001 update of the American Heart Association (AHA)/American College of Cardiology (ACC)
More informationPATIENT EDUCATION PACKET
Healthy Weight Exercise Healthy Diet Tobacco Use High Blood Pressure PATIENT EDUCATION PACKET Please take a moment and read through this educational packet. As part of a government program, we are required
More informationChapter 2: Identification and Care of Patients With Chronic Kidney Disease
Chapter 2: Identification and Care of Patients With Chronic Kidney Disease Introduction The examination of care in patients with chronic kidney disease (CKD) is a significant challenge, as most large datasets
More informationAntihypertensive Trial Design ALLHAT
1 U.S. Department of Health and Human Services Major Outcomes in High Risk Hypertensive Patients Randomized to Angiotensin-Converting Enzyme Inhibitor or Calcium Channel Blocker vs Diuretic National Institutes
More informationModelling Reduction of Coronary Heart Disease Risk among people with Diabetes
Modelling Reduction of Coronary Heart Disease Risk among people with Diabetes Katherine Baldock Catherine Chittleborough Patrick Phillips Anne Taylor August 2007 Acknowledgements This project was made
More informationHypertension Update Background
Hypertension Update Background Overview Aaron J. Friedberg, MD Assistant Professor, Clinical Division of General Internal Medicine The Ohio State University Wexner Medical Center Management Guideline Comparison
More information